在患有性结肠炎的患者中,针对美沙胺不耐受性的新型脱敏疗法
Kenji Kinoshita1, Shintaro Sawaguchi1, Kai Toyoshima1
1Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan.
概括
一个新的,简化的梅萨胺脱敏方案成功治疗了对该药物不耐受的性结肠炎患者. 这种安全的方法使所有参与者能够达到治疗性梅沙胺剂量,而没有严重的不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 梅沙胺是对轻度至中度性结肠炎 (UC) 的一线治疗.
- 梅萨拉胺不耐受会影响一些UC患者,限制治疗选择.
- 现有的脱敏方案往往是复杂的临床使用.
研究的目的:
- 开发和评估一项简化,替代性无敏化协议,用于UC患者的梅沙胺不耐受.
主要方法:
- 一个回顾性,单中心研究,涉及UC患者的梅沙胺不耐受.
- 逐渐增加梅萨拉胺的剂量,从每周50毫克开始,并进行调整.
- 一开始允许同时服用药物,但在协议完成之前取消.
主要成果:
- 在17名耐受不良患者中,有11人完成了没有住院治疗的方案.
- 所有成功消毒的患者都达到目标梅沙胺剂量 (3000-4000毫克/天).
- 在脱敏过程中没有报告任何严重不良事件.
结论:
- 开发的协议为UC患者的梅沙胺脱敏提供了一种成功和安全的方法.
- 这种简化方法可以改善梅沙胺不耐受症患者的治疗坚持.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
315
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
315
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131
Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110


